Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Corbus Pharmaceuticals Stock Down 2.9 %
CRBP Stock traded down $0.01 during midday trading on Friday, hitting $0.26. The stock had a trading volume of 2,667,527 shares, compared to its average volume of 532,829. The firm has a market cap of $32.16 million, a price-to-earnings ratio of -0.89 and a beta of 1.94. The business has a 50-day moving average of $0.27 and a two-hundred day moving average of $0.34. Corbus Pharmaceuticals has a 52-week low of $0.21 and a 52-week high of $1.32. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.81 and a quick ratio of 5.85.
Corbus Pharmaceuticals (NASDAQ:CRBP - Get Rating) last issued its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. As a group, equities research analysts forecast that Corbus Pharmaceuticals will post -0.24 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Separately, StockNews.com initiated coverage on Corbus Pharmaceuticals in a research note on Friday. They set a "hold" rating on the stock.